Research programme: antibacterials - Morphochem

Drug Profile

Research programme: antibacterials - Morphochem

Alternative Names: Bacterial topoisomerase I inhibitors - Morphochem; Enzyme inhibitors - Morphochem; MCB 1033; MCB 116; MCB-4657; MCB-4658; MCTI programme - Morphochem; Topoisomerase inhibitors - Morphochem; Topoisomerase IV inhibitors - Biovertis

Latest Information Update: 12 Jun 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Morphochem AG
  • Class Oxazolidinones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Bacterial infections

Most Recent Events

  • 15 Dec 2006 Suspended - Preclinical for Bacterial infections in Switzerland (unspecified route)
  • 15 Dec 2006 Suspended - Preclinical for Bacterial infections in USA (unspecified route)
  • 17 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the Bacterial Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top